Based on the Legend Biotech Corp stock forecast from 15 analysts, the average analyst target price for Legend Biotech Corp is USD 77.00 over the next 12 months. Legend Biotech Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Legend Biotech Corp is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Legend Biotech Corp’s stock price was USD 39.35. Legend Biotech Corp’s stock price has changed by -4.93% over the past week, -21.30% over the past month and -38.97% over the last year.
No recent analyst target price found for Legend Biotech Corp
No recent average analyst rating found for Legend Biotech Corp
Company Overview Legend Biotech Corp
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation. Read Less
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationall...Read More
Frequently Asked Questions About Legend Biotech Corp (LEGN) Stock
Based on ratings from 15 analysts Legend Biotech Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 26 buy, sell and hold ratings.
Unfortunately we do not have enough data on LEGN's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for LEGN is USD 77.00 over the next 12 months. The maximum analyst target price is USD 94 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on LEGN's stock to indicate if its overvalued.
The last closing price of LEGN's stock was USD 39.35.
The most recent market capitalization for LEGN is USD 8.30B.
Based on targets from 15 analysts, the average taret price for LEGN is projected at USD 77.00 over the next 12 months.
This means that LEGN's stock price may go up by +95.68% over the next 12 months.
We can't find any ETFs which contains Legend Biotech Corp's stock.
As per our most recent records Legend Biotech Corp has 2,200 Employees.
Legend Biotech Corp's registered address is 2101 Cottontail Lane, Somerset, NJ, United States, 08873.
You can get more information about it from Legend Biotech Corp's website at https://www.legendbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Legend Biotech Corp (LEGN) Stock
Based on ratings from 15 analysts Legend Biotech Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 26 buy, sell and hold ratings.
Unfortunately we do not have enough data on LEGN's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for LEGN is USD 77.00 over the next 12 months. The maximum analyst target price is USD 94 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on LEGN's stock to indicate if its overvalued.
The last closing price of LEGN's stock was USD 39.35.
The most recent market capitalization for LEGN is USD 8.30B.
Based on targets from 15 analysts, the average taret price for LEGN is projected at USD 77.00 over the next 12 months.
This means that LEGN's stock price may go up by +95.68% over the next 12 months.
We can't find any ETFs which contains Legend Biotech Corp's stock.
As per our most recent records Legend Biotech Corp has 2,200 Employees.
Legend Biotech Corp's registered address is 2101 Cottontail Lane, Somerset, NJ, United States, 08873.
You can get more information about it from Legend Biotech Corp's website at https://www.legendbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LEGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
